Dr. Antonarakis on available prostate cancer treatments driven by genetic testing

Emmanuel S. Antonarakis, MD, discusses FDA-approved treatments currently available for prostate cancer that are selected based on genetic testing of patients. Antonarakis is associate director for Translational Research at the University of Minnesota Medical School Masonic Cancer Center, as well as the Clark Endowed Professor of Medicine and director of Genitourinary Oncology in the Department of Medicine’s Division of Hematology, Oncology, and Transplantation